共 84 条
[1]
Mills W(1995)BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma J Clin Oncol 13 588-595
[2]
Chopra R(1997)BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors Bone Marrow Transplant 20 451-458
[3]
McMillan A(2013)Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma N Engl J Med 369 1681-1690
[4]
Pearce R(2015)High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma Leuk Lymphoma 56 2379-2387
[5]
Linch DC(2010)Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study Bone Marrow Transplant 45 1147-1153
[6]
Goldstone AH(2011)BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients Blood 118 3419-3425
[7]
Caballero MD(1988)Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ARA-C and dexamethasone (DHAP) Blood 71 117-122
[8]
Rubio V(2004)Follicular lymphoma international prognostic index Blood 104 1258-1265
[9]
Rifon J(2007)International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma J Clin Oncol 25 579-586
[10]
Heras I(2008)Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy-European Blood and Marrow Transplantation Mucositis Advisory Group J Clin Oncol 26 1519-1525